Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
07/2003
07/08/2003US6589557 Porous celecoxib matrices and methods of manufacture thereof
07/08/2003US6589554 Tablets quickly disintegrating in the oral cavity and process for producing the same
07/08/2003US6589552 Microstructure grains; fine particle size
07/08/2003US6589549 Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
07/08/2003US6589548 Controlled drug delivery system using the conjugation of drug to biodegradable polyester
07/08/2003US6589546 Polymeric coatings for controlled delivery of active agents
07/08/2003US6589535 Nutritional supplement based on blackcurrent seed oil
07/08/2003US6589507 Fast acting; chewable; acid binder, carbon dioxide efferves-cent compound, nonionic surfactant and swellable, gel forming polymer
07/08/2003US6589503 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
07/08/2003US6589286 Eustachian tube stent
07/08/2003CA2234426C Antibacterial composition for oral administration
07/08/2003CA2213608C Pharmaceutical composition stabilized with a basic agent
07/08/2003CA2131553C Use of alkylureas and hydroxyurea as contraceptive agents
07/08/2003CA2119610C Process for the preparation of a liposome dispersion under elevated pressure conditions
07/08/2003CA1341434C Compositions and methods for administering therapeutically active compounds
07/03/2003WO2003054543A2 Probe for mass spectrometry
07/03/2003WO2003054208A2 Method of modulating release of saccharides and uses thereof
07/03/2003WO2003054146A2 Self-assembly and mineralization of peptide-amphiphile nanofibers
07/03/2003WO2003054077A1 Cereal beta glucan compositions, methods of preparation and uses thereof
07/03/2003WO2003053991A1 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
07/03/2003WO2003053907A1 Emollients and cosmetic compositions
07/03/2003WO2003053501A1 Metered dose inhaler
07/03/2003WO2003053480A1 Composition for treating contact lenses in the eye
07/03/2003WO2003053475A1 Process for preparation of inclusion compounds between a non-steroidal anti-inflammatory drug and betacyclodextrin by microwave treatment
07/03/2003WO2003053474A2 Use of micro-organisms for a directed delivery of substances to specific parts of the gut
07/03/2003WO2003053473A2 Ph-sensitive polymeric conjugates of an anthracycline drug
07/03/2003WO2003053471A1 Aqueous sustained-release formulations of proteins
07/03/2003WO2003053470A2 Pulsed bio-agent delivery systems based on degradable polymer solutions or hydrogels
07/03/2003WO2003053465A2 Lyophilized preparation containing antibodies to the egf receptor
07/03/2003WO2003053463A2 Poxvirus-containing compositions and process for their preparation
07/03/2003WO2003053460A1 Crystalline compositions for controlling blood glucose
07/03/2003WO2003053457A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
07/03/2003WO2003053452A1 Heparin-containing ophthalmic agent
07/03/2003WO2003053442A1 Tempamine compositions and methods of use
07/03/2003WO2003053436A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
07/03/2003WO2003053432A1 5ht4 partial agonist pharmaceutical compositions
07/03/2003WO2003053431A2 Pharmaceutical compositions based on azetidine derivatives
07/03/2003WO2003053430A1 Drinkable preparation comprising ketoprofen and the use thereof in the simultaneous treatment of a group of animals for processes which are accompanied by fever, inflammation and/or pain
07/03/2003WO2003053418A1 Ultrapure oral fludara formulation with a fast releasing active substance
07/03/2003WO2003053415A1 Pharmaceutical composition comprising skim milk powder
07/03/2003WO2003053413A2 Sustained-release compositions
07/03/2003WO2003053411A1 Pulmonary delivery of aminoglycosides
07/03/2003WO2003053410A1 Particulate compositions
07/03/2003WO2003053409A1 Liposome composition for delivery of nucleic acid
07/03/2003WO2003053407A1 Liposomal delivery of vitamin e based compounds
07/03/2003WO2003053406A1 Fluorinated particles for inhalation & pharmaceutical formulation
07/03/2003WO2003053405A1 Method and composition for dry eye treatment
07/03/2003WO2003053404A1 Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
07/03/2003WO2003053403A2 Pharmaceutical suspension for oral administration
07/03/2003WO2003053402A1 Zero-order sustained released dosage forms and method of making the same
07/03/2003WO2003053401A2 Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
07/03/2003WO2003053400A1 Formulation & dosage form for the controlled delivery of therapeutic agents
07/03/2003WO2003053365A2 Syn3 compositions and methods
07/03/2003WO2003053357A2 Method and related composition employing nanostructures
07/03/2003WO2003053336A2 Methods for the treatment of peripheral neural and vascular ailments
07/03/2003WO2003053325A2 Microencapsulation of drugs by solvent exchange
07/03/2003WO2003053169A1 Soft drink replacer
07/03/2003WO2003053166A1 Food or pet food composition containing plant extract for bone health
07/03/2003WO2003053165A1 Matrix-forming composition containing pectin
07/03/2003WO2003053158A2 Malleable protein matrix and uses thereof
07/03/2003WO2003040211A3 Branched polymers and their conjugates
07/03/2003WO2003034983A3 Compositions and a new method for making a water-in-oil emulsion
07/03/2003WO2003026697A3 Organoleptically acceptable intraorally disintegrating compositions
07/03/2003WO2003026611A3 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
07/03/2003WO2003013476B1 Compositions and methods to prevent abuse of opioids
07/03/2003WO2003013440A3 Treatment and prevention of heat shock protein-associated diseases and conditions
07/03/2003WO2002099379A3 Breast homing peptides and methods of identifying same using aminopeptidase p
07/03/2003WO2002076497A3 Method and composition
07/03/2003WO2002072616A3 Transfection complexes
07/03/2003WO2002070549A3 Chimeric polypeptides of serum albumin and uses related thereto
07/03/2003WO2002058732A3 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
07/03/2003WO2002024754A8 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
07/03/2003US20030125800 Drug-delivery endovascular stent and method for treating restenosis
07/03/2003US20030125543 For addition to drugs as binder, disintegrant or excipient; bulk density; fluidized bed granulation
07/03/2003US20030125528 Comprises porcine somatotropin and o-vanillin, for improving feed efficiency in swine; opioid analgesics; freeze drying, spray drying; storage stabiity
07/03/2003US20030125523 Novel neuropilin/growth factor complexes and uses thereof
07/03/2003US20030125509 Indomethacin entrapped within polysaccaride (dextran) or proteins
07/03/2003US20030125391 Pharmaceutical solutions of modafinil compounds
07/03/2003US20030125388 5-Aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
07/03/2003US20030125387 Antioestrogens, capable of eliciting complete ablation of the trophic effects of oestrogens; cancer therapy
07/03/2003US20030125385 Prepared by mixing gamma-hydroxybutyrate and a pH-adjusting agent in an aqueous medium
07/03/2003US20030125376 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
07/03/2003US20030125350 Combination of formoterol and a tiotropium salt
07/03/2003US20030125313 Prophylaxis/treatment of respiratory system disorders; administered by inhalation; potentiation; reversible airways obstruction, e.g., asthma, chronic obstructive pulmonary diseases (COPD) (e.g. bronchitis, emphysema); infections
07/03/2003US20030125308 Antipruritic agents for external use
07/03/2003US20030125307 Transdermally administering a preparation containing only acetylsalicylic acid as an active ingredient; bronchial asthma, allergic rhinitis, atopic dermatitis; eczema, lichen Vidal; insect stings; pruritis; side effect reduction
07/03/2003US20030125294 Selective toxin expression in angiogenic endothelial cells
07/03/2003US20030125292 Synergistic stimulating immunoglobulin A (IgA) production by administering a nucleic acid encapsulated with a lipid and at least one antigen
07/03/2003US20030125290 Cancer treatment with a synthetic sequences
07/03/2003US20030125247 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein
07/03/2003US20030125244 Endoparasiticidal agents
07/03/2003US20030125242 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
07/03/2003US20030125239 Compositions for drug delivery
07/03/2003US20030125238 Hemoglobin-based oxygen carriers are prepared by reacting hemoglobin with oxidatively ring-opened polysaccharides such as hydroxyethyl starch or dextran, and storing the resultant conjugate under conditions which allow it to transform to a
07/03/2003US20030125237 Controlled release preparation of insulin and its method
07/03/2003US20030125236 Phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the
07/03/2003US20030125234 Alteration of protein stability
07/03/2003US20030124742 Conjugates targeted to target receptors
07/03/2003US20030124705 Thrombolytic agents; mucopolysaccharides; anticoagulants; proteolytic enzymes; blood coagulation factor x
07/03/2003US20030124613 Epitope testing using soluble HLA
1 ... 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 ... 1712